Relative Bioavailability of Empagliflozin (BI 10773) (Final Formulation) Compared to Empagliflozin (BI 10773 XX) (Trial Formulation 2) in Healthy Male and Female Volunteers

NCT01242176 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

24

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy

Interventions

DRUG: BI 10773 XX (Trial Formulation 2)
DRUG: BI 10773 (Final Formulation)

Sponsor

Boehringer Ingelheim